Ibnsina Pharma results, Q2 2024
Net profit, assets, equity and cash flow for Q2 2024, against the same period a year earlier, from the published financial statements.
Net profit208 millionEGP · −2.6% vs the same period a year earlier
Total assets28.64 billionEGP · +54.4% vs the same period a year earlier
Shareholders' equity2.03 billionEGP · +40.2% vs the same period a year earlier
Operating cash flow-927 millionEGP · −272.9% vs the same period a year earlier
In short
- Ibnsina Pharma's net profit for Q2 2024 was about 208 million EGP, down −2.6% from 214 million EGP in Q2 2023.
- Total assets at the end of Q2 2024 were about 28.64 billion EGP, and shareholders' equity about 2.03 billion EGP.
- Operating cash flow for Q2 2024 was negative at 927 million EGP.
Key lines against the same period a year earlier
This periodQ2 2023Change
Net profit208 million214 million−2.6%
Gross profit4.53 billion2.63 billion+72.3%
Total assets28.64 billion18.55 billion+54.4%
Total liabilities26.61 billion17.1 billion+55.6%
Shareholders' equity2.03 billion1.45 billion+40.2%
Total liabilities and equity28.64 billion18.55 billion+54.4%
Operating cash flow-927 million536 million−272.9%
Investing cash flow-260 million-280 million+7.2%
Financing cash flow891 million744 million+19.9%
Net change in cash-295 million406 million−172.6%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Ibnsina Pharma's Q3 2026 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy